Featured Stories

5:28 PM May 23, 2019
Anima opens new target space in translational control

Anima Biotech’s answer to undruggable targets is to go after the machinery that turns their mRNA into protein, adding a new approach to the gene regulation toolkit. The strategy should give Anima a leg up over competitors looking to bind RNA directly, in terms of target stability, tissue selectivity and the ability to tune protein expression up or down....

4:47 PM May 23, 2019
As polygenic risk scores mature, opportunities emerge for disease interception

With comprehensive genetic risk profiling inching closer to clinical use, the biggest opportunity for drug developers could be the new territory it opens up in disease prevention and interception, particularly for common diseases.

Much of industry has piled into Orphan diseases, which are often caused by mutations in single genes, leaving more prevalent...

BioCentury Management

Karen Bernstein, Ph.D., Co-Founder & Chairman

Karen is co-founder and chairman of BioCentury Inc. and was Editor-in-Chief from October 1992 to August 2015. She is a director at Ovid Therapeutics Inc., which is developing drugs for orphan diseases of the brain; at Codiak Biosciences Inc., which is engineering exosomes to target new therapeutic spaces; and at Achaogen Inc., which markets Zemdri plazomicin to treat cUTI. She is on the board of trustees of the Keck Graduate Institute of the Applied Life Sciences and is a member of the board of advisors of KGI's School of Pharmacy. She serves on the board of overseers of Scripps Research. Karen holds a Ph.D. in political science from Stanford University and a B.A. in politics and history from Brandeis University, where she served for many years as a member of the Brandeis University Science Advisory Council. In 2005, the annual gathering of biotechnology chief executive officers at The Biotech Meeting in Laguna Niguel, Calif., inducted Karen into their Hall of Fame, citing her lifetime contribution to the biotech community. In 2007, Karen received a Special Recognition award at the American Liver Foundation's Salute to Excellence, honoring individuals who have made an outstanding contribution to biotechnology and medical innovation. In 2013, she was named as one of the 100 Women of Influence in Silicon Valley by the Silicon Valley Business Journal. In 2015, Scientific American named Karen as one of The WorldVIEW 100 most influential people in biotech today. In 2016, she was named Commentator of the Year by the European Mediscience Awards.

David Flores, Co-Founder, President & CEO 

David has devoted more than 25 years to developing information products for biotechnology executives and investors. He is a graduate of the University of California at Berkeley and holds an MBA from Stanford University. David is a member of the Advisory Board of the Innovation and New Ventures Office (INVO) at Northwestern University and a member of the Advisory Council of the Keck Graduate Institute of the Applied Life Sciences. He also has served as a member of the Stanford Graduate School of Business Management Board. In 1996, David and BioCentury Co-Founder & Chairman Karen Bernstein were honored with the Special Recognition Award given by the annual gathering of biotechnology chief executive officers in Laguna Niguel, Calif., citing BioCentury's ongoing contributions to the industry.

Simone Fishburn, Ph.D., Vice President and Executive Editor, BioCentury and BioCentury Innovations

Simone serves as Vice President and Executive Editor of BioCentury and BioCentury Innovations. She was previously Editor of BioCentury Innovations, and prior to that was a senior editor for SciBX: Science-Business eXchange, a joint publication between BioCentury and Nature Publishing Group. Simone also serves as an advisor on two university translational programs: the CTSI Catalyst program at the University of California San Francisco (UCSF) and the SPARK program at Stanford University. Prior to joining BioCentury in 2013, Simone spent nine years in preclinical drug development at Nektar Therapeutics, where she headed the pain program as director of translational research, and two years at Exponent Inc., where she assisted small and large biotechs on a range of scientific projects. Before she entered the industry, Simone spent eight years in academia, first as a post-doc at UCSF and then performing research at the Weizmann Institute of Science. Simone is also active in programs to advance women's careers; she is a Board member of Women In Bio and served as president from 2013-2014. She is a Fulbright scholar, and holds a Ph.D. in molecular pharmacology from the Weizmann, and an M.A. and B.A. in pharmacology from Cambridge University.

Bennet Weintraub, Vice President & Chief Financial Officer

Bennet Weintraub, Vice President & Chief Financial Officer Bennet, who joined BioCentury in 2004, has had an extensive career as a senior financial executive for development stage biotechnology and technology companies, having taken two companies public, and having completed numerous equity and debt financings and M&A transactions. He was CFO at InterMune, Valentis and Technology Modeling Associates, and held senior financial positions at Metra Biosystems and Advanced Polymer Systems. Bennet received his B.A. in Mathematical Economics from Pomona College and earned his MBA from Harvard University.

Eric Pierce, Publisher

Eric joined BioCentury in 1993 as its first Staff Writer, and became chief financial writer in 1996 when he originated "Ebb & Flow," BioCentury's weekly capital markets column. As Senior Editor for News, Eric managed BioCentury's news operations until 2004, when he joined the management team as Associate Publisher, and in 2007 was named Publisher. He holds an A.B. in Communication from Stanford University and completed graduate studies at the Mass Media Institute at Stanford, with an emphasis on broadcast journalism.

Susan Morgan, Director of Administration & Human Resources

Susan joined BioCentury in 2006, bringing with her extensive experience in the legal profession in New York. She holds a B.A. in Political Science from Fairfield University and a J.D. from Fordham University School of Law.